MX9702431A - Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same. - Google Patents

Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same.

Info

Publication number
MX9702431A
MX9702431A MX9702431A MX9702431A MX9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A MX 9702431 A MX9702431 A MX 9702431A
Authority
MX
Mexico
Prior art keywords
methods
enteric bacteria
bacteria
enteric
vaccines
Prior art date
Application number
MX9702431A
Other languages
Spanish (es)
Inventor
John L Pace
Richard I Walker
Steven M Frey
Original Assignee
Microcarb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/538,543 external-priority patent/US5681736A/en
Application filed by Microcarb Inc filed Critical Microcarb Inc
Publication of MX9702431A publication Critical patent/MX9702431A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/045—Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Helicobacter species. Also there are other enteric bacteria which are useful for the disclosed invention. One type, Campylobacter jejuni is graphically depicted wherein the results of high-performance liquid chromatography of monosaccharides from surface extract hydrolysates of C. jejuni are shown.
MX9702431A 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same. MX9702431A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31840994A 1994-10-05 1994-10-05
US08/538,543 US5681736A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US08/538,545 US5679564A (en) 1994-10-05 1995-10-03 Methods for producing enhanced antigenic campylobacter bacteria and vaccines
PCT/US1995/013196 WO1996011258A1 (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same

Publications (1)

Publication Number Publication Date
MX9702431A true MX9702431A (en) 1998-05-31

Family

ID=27405987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702431A MX9702431A (en) 1994-10-05 1995-10-04 Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same.

Country Status (16)

Country Link
EP (1) EP0804542A4 (en)
JP (1) JP3394047B2 (en)
CN (1) CN1168693A (en)
AU (1) AU704283B2 (en)
BR (1) BR9509276A (en)
CA (1) CA2202027A1 (en)
CZ (1) CZ104397A3 (en)
FI (1) FI971403A (en)
HU (1) HUT77876A (en)
IL (1) IL115521A0 (en)
MX (1) MX9702431A (en)
NO (1) NO971519L (en)
NZ (1) NZ295907A (en)
PL (1) PL182700B1 (en)
SG (2) SG73509A1 (en)
WO (1) WO1996011258A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ104297A3 (en) * 1994-10-05 1997-11-12 Microcarb Methods of producing higher antigenic heliobacter spp. and vaccines containing thereof
CA2525540A1 (en) * 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
US20100074846A1 (en) * 2006-03-17 2010-03-25 Ellis John A Campylobacter Vaccines and Methods of use
EP2161035B1 (en) * 2007-05-28 2019-08-21 Daiichi Sankyo Company, Limited Bordetella parapertussis-containing whole-cell vaccine composition
CN107513553B (en) * 2017-09-18 2021-05-18 江南大学 Method for screening lactobacillus with antagonistic campylobacter jejuni infection function
CN109633151B (en) * 2018-12-26 2022-03-11 西北农林科技大学 Salmonella enteritidis detection method, test strip and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096650A1 (en) * 1991-09-18 1993-03-21 Keith E. Langley Hepatitis b vaccine formulation incorporating a bile acid salt

Also Published As

Publication number Publication date
IL115521A0 (en) 1996-06-18
CZ104397A3 (en) 1998-06-17
JPH10507347A (en) 1998-07-21
SG73510A1 (en) 2000-06-20
EP0804542A1 (en) 1997-11-05
CN1168693A (en) 1997-12-24
WO1996011258A1 (en) 1996-04-18
NO971519L (en) 1997-05-27
EP0804542A4 (en) 1998-10-28
CA2202027A1 (en) 1996-04-18
AU704283B2 (en) 1999-04-15
NO971519D0 (en) 1997-04-03
PL319580A1 (en) 1997-08-18
HUT77876A (en) 1998-09-28
PL182700B1 (en) 2002-02-28
FI971403A (en) 1997-06-04
AU3956195A (en) 1996-05-02
FI971403A0 (en) 1997-04-04
NZ295907A (en) 1999-04-29
JP3394047B2 (en) 2003-04-07
SG73509A1 (en) 2000-06-20
BR9509276A (en) 1997-11-18

Similar Documents

Publication Publication Date Title
ES500567A0 (en) PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS.
MY133780A (en) Vaccine composition
IL86583A0 (en) Vaccine containing a derivative of a microbe and method for the production thereof
MY113428A (en) Hepatitis b vaccine
GB8412207D0 (en) Antigenic preparations
NZ223009A (en) Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
HUP9903770A2 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
MY128999A (en) Purification of hbv antigens for use in vaccines
EP0722338A4 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
MX9702432A (en) Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same.
MX9702431A (en) Methods for producing enhanced antigenic enteric bacteria and vaccines comprising same.
DE69527986T2 (en) ANTIGENE MEDICINE FOR TREATMENT OR PREVENTION
IE42622L (en) Protective antigen from pertussis.
ZA905927B (en) Biological preparation and its use
HK1004555A1 (en) Process
WO2004033483A3 (en) Liposomal system and method of using same
UA42741C2 (en) Peptide of mastitis vaccine (variants), the peptide of complex antigenic idea (variants), pharmaceutical composition (variants)
ATE353226T1 (en) ADJUVANT COMPOSITION CONTAINING FHA OR AN FHA FRAGMENT IN FREE FORM
AU2579600A (en) Product and method for obtaining specific immunisation with one or more antigens
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees